aTyr Pharma’s Efzofitimod Misses Primary Endpoint in Phase 3 Trial
aTyr Pharma said efzofitimod missed the primary endpoint in its Phase 3 pulmonary sarcoidosis trial.
Related stories
Coal India Q2 Profit Rises 53% as Revenue Reaches Rs 44,178.74 Crore
Revenue from operations rose to Rs 44,178.74 crore year on year. The board approved a second interim dividend of Rs 10.25 per share.
M impact | EQUITY | Oct 30, 2026, 02:32 AM UTC
Daewoo Engineering & Construction Wins Won 330.3 Billion Order
Daewoo Engineering & Construction won an order worth 330.3 billion won.
M impact | EQUITY | Oct 30, 2026, 02:31 AM UTC
Daito Trust reports interim profit up 28.6%, forecasts annual profit up 10.1%
Daito Trust reported consolidated interim profit of 641.75億円, up 28.6%, and forecast profit of 1090.00億円 for the fiscal year ending March, up 10.1%.
M impact | EQUITY | Oct 30, 2026, 02:31 AM UTC
Asian session market picture: S&P 500 -1.04%, Nasdaq 100 -2.25%; USD/JPY -0.12%, WTI +1.81%, 1810 leads volume
Asian session market picture. US index futures: S and P futures is down 1.04 percent, Nasdaq futures is down 2.25 percent, Dow futures is down 0.26 percent and Russell futures is d
M impact | EQUITY | Oct 30, 2026, 02:30 AM UTC
Geely Auto Quarterly Earnings Rise 28% Amid Overhaul
Geely Auto reported a 28% jump in quarterly earnings. The commentary says the market continues to treat the Chinese automaker poorly despite changes to electrification, succession
M impact | EQUITY | Oct 30, 2026, 02:27 AM UTC
Aluminum Corp of China H Shares Rise 2.7% as Q3 Net Profit Climbs
Aluminum Corp of China’s H shares rose 2.7%; its A shares gained as much as 1.8% Friday morning. Third-quarter net profit increased year over year.
M impact | EQUITY | Oct 30, 2026, 02:26 AM UTC